BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-A1904 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-A1904\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06547736-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT06547736)
DESCRIPTION:SHR-A1904\, phase 2.\nStudy: Exploratory Platform Research on P
 recision Therapy of Advanced Pancreatic Cancer\nEstimated primary completi
 on: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-a
 1904#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06547736
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649292-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:SHR-A1904: Phase 3 readout est. (NCT06649292)
DESCRIPTION:SHR-A1904\, phase 3.\nStudy: SHR-A1904 Compared With Investigat
 or's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line A
 dvanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma\
 nEstimated primary completion: 20 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/shr-a1904#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06649292
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700719-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20271128
DTEND;VALUE=DATE:20271129
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT07700719)
DESCRIPTION:SHR-A1904\, phase 2.\nStudy: SHR-A1904 in Advanced Colorectal C
 ancer: an Exploratory Study\nEstimated primary completion: 28 November 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1904#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07700719
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT07102901)
DESCRIPTION:SHR-A1904\, phase 2\, Gastric Cancer.\nStudy: Safety and Effica
 cy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro
 -oesophageal Junction Adenocarcinoma\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1904#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071029
 01
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350006-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:SHR-A1904: Phase 1 readout est. (NCT06350006)
DESCRIPTION:SHR-A1904\, phase 1.\nStudy: SHR-A1904 Combinations in CLDN18.2
 -Positive Advanced Solid Tumor\nEstimated primary completion: 30 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1904#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06350006
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520357-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT07520357)
DESCRIPTION:SHR-A1904\, phase 2.\nStudy: A Phase II Clinical Study of SHR-A
 1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocr
 ine Carcinoma\nEstimated primary completion: 28 February 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/shr-a1904#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07520357
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT06881017)
DESCRIPTION:SHR-A1904\, phase 2\, Gastric Cancer.\nStudy: Establishment of 
 Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on
  Novel Molecular Subtyping\nEstimated primary completion: 1 August 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1904#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450976-11072@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT07450976)
DESCRIPTION:SHR-A1904\, phase 2.\nStudy: A Study of SHR-A1904 in Previous S
 ystemic Treatment Failed Biliary Tract Cancer\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr
 -a1904#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07450976
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
